NCT06176339View on ClinicalTrials.gov

"Assessing the Clinical Utility of Adding Pentoxifylline to Neoadjuvant Chemotherapy Protocols in Breast Cancer Patients"

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

70

Participants

Timeline

Start Date

December 15, 2023

Primary Completion Date

August 30, 2024

Study Completion Date

September 30, 2024

Conditions
Breast Cancer Female
Interventions
DRUG

Pentoxifylline Oral Tablet

Pentoxifylline 400 mg extended-release oral tablets will be administered orally three times per day through the chemotherapy cycles.

DRUG

Placebo

Placebo tablets will be administered orally three times per day through the time of the chemotherapy cycles.

Trial Locations (1)

Unknown

Oncology center of Mansoura University, Al Mansurah

All Listed Sponsors
lead

Mansoura University

OTHER

NCT06176339 - "Assessing the Clinical Utility of Adding Pentoxifylline to Neoadjuvant Chemotherapy Protocols in Breast Cancer Patients" | Biotech Hunter | Biotech Hunter